Ember Therapeutics, Inc.: Series A $34.1M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, X - Therapeutic Platform, XX - MA

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

HealthTap, Inc.: Series A $11.5M

Posted in I - Series A, Q - 4Q11, R - WEST, X - TeleMedicine, XX - CA

HealthTap (Palo Alto, CA) a web-based company focused on applications for the exchange of health information between patients and physicians, closed a $11.5M Series A financing. Participants include Mayfield Fund, Mohr Davidow Ventures and Innovation Endeavors.

TopiVert, Ltd.: Series A $12.5M

Posted in I - Series A, Q - 4Q11, R - INTERNATIONAL, X - Inflammation

TopiVert (United Kingdom) a development-stage pharmaceutical company focused on topical medicines for inflammatory diseases of the eye and gut, closed a $12.5M Series A financing. Participants include Imperial Innovations Group and SV Life Sciences.

MedLumics: Series A $4.7M

Posted in I - Series A, Q - 4Q11, R - INTERNATIONAL, X - Device (Imaging), X - Device (Ophthalmology)

MedLumics (Spain) a development-stage diagnostic device company focused on optical coherence tomography imaging for ophthalmology and intravascular imaging in cardiology, dermatology and dentistry, closed a $3.25M Series A financing. Participants include Ysios Capital Partners and Caixa Capital.

Cervilenz, Inc.: Series A $8.4M

Posted in I - Series A, Q - 4Q11, R - MID WEST, X - Device (Women's Health), XX - OH

Cervilenz (Chagrin Falls, OH) a development-stage device company focused on the a disposable to identify and manage pregnant women at high risk for preterm birth, closed an $8.35M Series A financing. Participants include Arboretum Ventures and Chrysalis Ventures.

Leonardo Biosystems, Inc.: Series A $1.25M

Posted in I - Series A, Q - 4Q11, R - SOUTH WEST, X - Delivery, XX - TX

Leonardo Biosystems (Houston, TX) a development-stage biopharmaceutical company focused on drug delivery technology, closed a $1.25M Series A financing, bringing the total round to $2.5M. Participants include Texas Emerging Technology Fund.

Tangent Medical Technologies, Inc.: Series A $4.5M

Posted in I - Series A, Q - 4Q11, R - MID WEST, X - Device (Delivery), XX - MI

Tangent Medical Technologies (Ann Arbor, MI) a development-stage medical device company focused on peripheral intravenous delivery systems, closed a $4.5M Series A financing. Participants include Arboretum Ventures, Flagship Ventures and Osage Ventures.

Atox Bio.: Series A $3.25M

Posted in I - Series A, Q - 4Q11, R - INTERNATIONAL, X - Antiinfective, X - Inflammation, X - Sepsis

Atox Bio (Israel) a clinical-stage biotechnology company focused on small molecules for the treatment of severe bacterial infections, sepsis, necrotizing soft tissue infections and intra-abdominal infections, closed a $3.25M Series A financing. Participants include Esperante.

Provenance Biopharmaceuticals, Corp.: Series A $8M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Immunology, X - Oncology, XX - MA

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

PharmacoFore, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Addiction, X - CNS, X - Neurology, X - Pain, XX - CA

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

Innopharma, Inc.: Series A $15M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Device (Delivery), X - Generics, X - Injectable, X - Opthalmology, XX - NJ

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

Karyopharm Therapeutics, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Inflammation, X - Oncology, XX - MA

Karyopharm Therapeutics (Natick, MA) a preclinical-stage small molecule company focusing on the treatment of cancer and inflammation, closed a $10M Series A financing, bringing the total round to $30M. Participants include Chione.

NanoDetection Technology, Inc. Series A $2.3M

Posted in I - Series A, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), XX - OH

NanoDetection Technology (Cincinnati, OH) a development-stage in vitro poc diagnostic platform focused on uses in healthcare, food safety and bioterrorism, closed a $2.3M Series A financing. Participants include CincyTech.
Thanx for your patience as we catch-up.

« Previous Entries

to top of page...